Novo Nordisk: presents CagriSema results

(CercleFinance.com) - Novo Nordisk has announced top-line results from a phase 3 trial of the global REDEFINE program.


REDEFINE 2 is a 68-week efficacy and safety trial evaluating weekly subcutaneous administration of CagriSema (a fixed-dose combination of 2.4 mg cagrilintide and 2.4 mg semaglutide) versus placebo.

The trial involved 1,206 randomized people with obesity or overweight and type 2 diabetes, with a mean initial body weight of 102 kg.

The trial met its primary endpoint by demonstrating statistically significant and greater weight loss at week 68 with CagriSema compared with placebo.

' 'The results of the REDEFINE 2 trial confirmed the superior efficacy of CagriSema in overweight or obese people with type 2 diabetes,' said Martin Holst Lange, executive vice president of development at Novo Nordisk.

'We look forward to presenting this second pivotal trial to the regulatory authorities with the aim of making this next-generation therapy available to the millions of patients who need it. '

Copyright (c) 2025 CercleFinance.com. All rights reserved.